Coca-Cola is facing a lawsuit over claims that its Simply Orange Juice contains high levels of toxic chemicals known as PFAS, or “forever chemicals.”
According to the plaintiff, Joseph Lurenz, the beverage company deceived customers by marketing the juice as all-natural, despite third-party testing finding PFAS levels hundreds of times higher than federal limits for drinking water.
Exposure to high PFAS levels can increase the risk of various health problems, including cancer, fetal complications, liver disease, kidney or testicular cancer, and increased cholesterol levels.
The plaintiff, which claims the defendants knew the product contained PFAS but failed to disclose the information to consumers, is seeking monetary compensation, damages, and penalties for the company.
It is unknown how PFAS chemicals contaminated the water used to make the juice, and if the chemicals could also be in the packaging.


US Auto Industry Urges Trump to Block Chinese EV Market Access
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide
Judge Rules Use of Military Lawyers in Civilian Prosecutions Is Lawful
US Inflation Expected to Rise Again in April as Fed Signals Higher Interest Rates
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch
Asian Currencies Slide as Iran Tensions Boost Dollar and Oil Prices
OpenAI-Microsoft Deal Sets $38 Billion Revenue-Sharing Cap Ahead of Potential IPO
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some
Bolsonaro Discharged After Shoulder Surgery Amid Ongoing Legal Troubles
Morgan Stanley Bets on Optical Component Stocks in Greater China Tech Sector
US Stock Futures Slip as Trump Rejects Iran Peace Proposal Amid Rising Middle East Tensions
RFK Jr. Expands CDC Vaccine Advisory Panel's Scope Amid Legal Battles
CSL Shares Crash as Profit Warning and $5 Billion Impairment Shake Investors
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone
Novo Nordisk Shares Tumble After CagriSema Misses Key Trial Endpoint
Federal Appeals Court Allows Texas SB4 Immigration Law Enforcement to Proceed 



